-+ 0.00%
-+ 0.00%
-+ 0.00%

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes

Reuters·03/26/2026 11:05:25

Please log in to view news